title: Bidirectional changes in synapsin I phosphorylation at MAP kinase-dependent sites by acute neuronal excitation in vivo.
abstract: Synapsin I is a synaptic vesicle-associated protein which is phosphorylated at multiple sites by various kinases. It has been proposed to play a role in the regulation of neurotransmitter release and the organization of cytoskeletal architecture in the presynaptic terminal. To better understand the physiological regulation of its phosphorylation in vivo, we induced acute, reversible neuronal excitation by electroconvulsive treatment (ECT) in rats, and studied its effects on synapsin I phosphorylation at sites 3, 4/5 and 6 by immunoblot analyses of homogenates from hippocampus and parietal cortex using phospho-site-specific antibodies. A decrease in phosphorylation at all sites was observed soon after the electrical stimulation, followed by a large increase in phosphorylation at site 4/5 peaking at 5 min and a moderate increase in phosphorylation at site 6 peaking at 20 min. Systemic injection of SL327, a mitogen-activated protein kinase (MAPK) kinase inhibitor, prior to ECT, suppressed the increase in phospho-site 4/5 level, as well as that in MAPK activity, but not that in phospho-site 6 level. Thus, phosphorylation at site 4/5 of synapsin I has been shown to be regulated by MAPK in vivo.
authors.affiliation: Laboratory of Neurochemistry, National Institute for Physiological Sciences, Myodaiji, Okazaki, Japan. yamagata@nips.ac.jp
authors.forename: Yoko
authors.initials: Y
authors.lastname: Yamagata
authors.forename: Jasmina N
authors.initials: JN
authors.lastname: Jovanovic
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Czernik
authors.forename: Paul
authors.initials: P
authors.lastname: Greengard
authors.forename: Kunihiko
authors.initials: K
authors.lastname: Obata
mesh_terms: D000607:Aminoacetonitrile / Q000031:analogs & derivatives; D000818:Animals; D001665:Binding Sites / Q000187:drug effects / Q000502:physiology; D051360:Cyclin-Dependent Kinase 5; D018844:Cyclin-Dependent Kinases / Q000378:metabolism; D004597:Electroshock; D004789:Enzyme Activation / Q000502:physiology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006624:Hippocampus / Q000737:chemistry / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D015151:Immunoblotting; D008297:Male; D020928:Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D009474:Neurons / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism*; D010296:Parietal Lobe / Q000737:chemistry / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D010766:Phosphorylation / Q000187:drug effects; D011480:Protease Inhibitors / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D012640:Seizures / Q000378:metabolism; D016704:Synapsins / Q000378:metabolism*
chemical_list: D004791:Enzyme Inhibitors; D011480:Protease Inhibitors; C424127:SL 327; D016704:Synapsins; D000607:Aminoacetonitrile; D051360:Cyclin-Dependent Kinase 5; C495907:Cdk5 protein, rat; D018844:Cyclin-Dependent Kinases; D020928:Mitogen-Activated Protein Kinases